Update shared on08 Aug 2025
OrthoPediatrics' valuation outlook is stable, with both the future P/E and net profit margin essentially unchanged, resulting in the consensus analyst price target holding steady at $33.86.
What's in the News
- Expanded the OrthoPediatrics Specialty Bracing division with new clinics in California, Ohio, Colorado, New York, and internationally into Ireland, enhancing presence in key hospitals and entering new markets.
- Raised 2025 revenue guidance to $237–$242 million, representing 16–18% year-over-year growth expectations.
- Launched the 3P Pediatric Plating Platform Hip System in the US, with initial surgical cases and growing procedural volume reported.
- Achieved a milestone in the Global POISE Study, now monitoring over 600 implants in 300+ pediatric patients across 13 active international sites to inform ongoing product refinement.
- Added as a constituent to several Russell growth and microcap indexes, increasing market visibility and potential institutional ownership.
Valuation Changes
Summary of Valuation Changes for OrthoPediatrics
- The Consensus Analyst Price Target remained effectively unchanged, at $33.86.
- The Future P/E for OrthoPediatrics remained effectively unchanged, moving only marginally from 26.40x to 26.06x.
- The Net Profit Margin for OrthoPediatrics remained effectively unchanged, moving only marginally from 12.34% to 12.49%.
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.